Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Accumulated Expenses (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Accumulated Expenses for 5 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 52.85% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, down 52.85%, while the annual FY2025 figure was $3.7 million, 52.85% down from the prior year.
  • Accumulated Expenses hit $3.7 million in Q4 2025 for Kezar Life Sciences, down from $3.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.7 million in Q3 2023 and bottomed at $849000.0 in Q1 2021.
  • Average Accumulated Expenses over 5 years is $5.3 million, with a median of $5.3 million recorded in 2022.
  • Year-over-year, Accumulated Expenses surged 543.59% in 2023 and then tumbled 59.36% in 2025.
  • Kezar Life Sciences' Accumulated Expenses stood at $1.6 million in 2021, then plummeted by 38.67% to $1.0 million in 2022, then soared by 543.59% to $6.5 million in 2023, then increased by 22.43% to $7.9 million in 2024, then plummeted by 52.85% to $3.7 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $3.7 million, $3.9 million, and $4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.